Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months.

Trial Profile

Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Heart failure; Hypertension
  • Focus Biomarker; Therapeutic Use
  • Acronyms CAN-DHF
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Oct 2012 Planned number of patients changed from 300 to 350.
    • 10 Feb 2009 Actual patient numbers (22) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top